Efficacy of Mavacamten Combined With Radiofrequency Ablation in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Inclusion criteria

• . At least 18 years old at screening.
• . Body weight was greater than 45 kg at screening.
• . Diagnosed with obstructive hypertrophic cardiomyopathy (oHCM) consistent with current American College of Cardiology Foundation/American Heart Association, European Society of Cardiology, and Chinese Society of Cardiology guidelines, ie, satisfy criteria below (criteria to be documented by the echocardiography core laboratory): A. Had unexplained left ventricular (LV) hypertrophy with nondilated ventricular chambers in the absence of other cardiac (eg, hypertension, aortic stenosis) or systemic disease and with maximal LV wall thickness ≥15 mm (or ≥13 mm with positive family history of hypertrophic cardiomyopathy), as determined by core laboratory interpretation, and B. Had left ventricular outflow tract (LVOT) peak gradient ≥50 mm Hg during screening as assessed by echocardiography at rest or after Valsalva maneuver (confirmed by echocardiography core laboratory interpretation).
• . Had documented LV ejection fraction (LVEF) ≥55% by echocardiography core laboratory read of screening TTE at rest.
• . Had a valid measurement of Valsalva LVOT peak gradient at screening as determined by echocardiography core laboratory.
• . Had New York Heart Association (NYHA) class II or III symptoms at screening.
• . Had documented oxygen saturation at rest ≥90% at screening.
• . Study participants were able to understand and comply with the study procedures, understand the risks involved in the study, and provided written informed consent according to national, local, and institutional guidelines before the first study-specific procedure.